We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Assay for Prions Responsible for Mad Cow Disease

By HospiMedica staff writers
Posted on 25 Jul 2006
An assay is being developed to determine the presence of prions in humans before symptoms of variant Creutzfeldt-Jakob disease (vCJD) appear. More...
Since the silent vCJD phase can last 40 years in humans, such an assay would reveal the extent of the problem and stop further infection via transfusions and transplants.

In the July 7, 2006, issue of the journal Science, Professor Claudio Soto and colleagues at the University of Texas Medical Branch at Galveston (UTMB, Galveston, TX, USA) described experiments they expect will lead to a test that will enable them to estimate how many people are infected with the human form of mad cow disease. The scientists detected prions--the infectious proteins responsible for such brain-destroying disorders as bovine spongiform encephalopathy (BSE) in cattle and vCJD in humans--in the blood of hamsters in as few as 20 days after the animals had been infected. That discovery occurred about three months before the hamsters began showing clinical symptoms of the disease.

To detect the very small quantities of prions found in blood samples, Professor Soto, assistant professor Joaquin Castilla, and research assistant Paula Saá used a technique known as protein misfolding cyclic amplification (PMCA), invented by the group. PMCA greatly accelerates the process by which prions convert normal proteins to misshapen infectious forms.

"With this method, for the first time we have detected prions in what we call the silent phase of infection,” said Prof. Soto. "This result is an important step toward a practical biochemical test that will determine how common variant CJD is, and keep contaminated blood and organs from spreading it further.” In a move toward making a human test commercially available, Prof. Soto and UTMB recently formed a startup company dubbed "Amprion.”

"All our effort so far has been to prove the scientific concepts, so we're building this company to go into issues of development, scalability and practicality,” Prof. Soto said. "We are hopeful that development of this technology into a useful blood test will be a pretty straightforward process.”





Related Links:
University of Texas Medical Branch at Galveston

Gold Member
12-Channel ECG
CM1200B
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Hybrid Arch Device
Neo EDE
POC Respiratory/Sore Throat Test
BIOFIRE SPOTFIRE (R/ST) Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: New findings show that chemotherapy plus immunotherapy before surgery produced greater tumor destruction than immunotherapy alone in head and neck cancer patients (Image Credit: Adobe Stock)

Combination Therapy Before Surgery Drives Stronger Tumor Reduction in Head and Neck Cancer

Patients with head and neck cancer who are scheduled for surgery often face a waiting period with limited treatment, creating an opportunity to reduce viable tumor burden before the operation.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.